The Magazine for Sleep Professionals
Tuesday, July 28, 2026
HoneyNaps, an AI-based sleep medicine company, announced that SOMNUM V3.0, its AI diagnosis software for polysomnography (PSG) analysis, has received U.S. Food and Drug Administration (FDA) clearance under clearance number K253390. SOMNUM is clinical decision support software designed to assist medical professionals in analyzing PSG data, including sleep staging and […]
Fisher & Paykel Healthcare has announced the United States launch of its newest nasal PAP mask for treating obstructive sleep apnea, the F&P Nova Nasal mask. Building on the success of the F&P Nova Micro™ and F&P Solo™ masks, the new F&P Nova Nasal delivers advanced technology to enhance mask […]
Daybreak, one of the leading providers of fully at-home sleep apnea diagnosis and treatment, today announces the appointment of Robert Miller, RPSGT, as its new Senior Vice President of Commercial Strategy. The appointment marks a pivotal next step as the company expands its national presence and deepens its dedication to transforming how obstructive […]
Topline: Patients with type 2 diabetes (T2D) who experienced sleep impairments, including short sleep duration, snoring, and insomnia symptoms, were more likely to face an increased risk for diabetes distress. In particular, daytime coping difficulties due to sleep problems showed a notably prominent association with diabetes distress. Methodology: Researchers in Norway conducted a cross-sectional […]
Fisher & Paykel Healthcare is launching a new advertising campaign called ‘Powered by Curiosity’, which highlights the performance of the company’s full-face masks for treating obstructive sleep apnea. After recent new product launches in the nasal and nasal pillows category (F&P Solo™ and F&P Nova Micro™), this campaign focuses on […]
A significant number of people in America are walking around with undiagnosed sleep disorders. Recent studies indicate 14.5 percent of adults in the U.S. have difficulty falling asleep, and 17.8 percent had difficulty staying asleep.1 While these alarming statistics highlight the urgent need for sleep disorder testing and treatment nationwide, […]
Recent research has elevated the management of obesity in patients with sleep disorders to a prominent position in clinical practice. Obesity has been capturing attention across social media, mainstream news, and even in cultural references such as South Park specials and Jimmy Kimmel’s 2023 Oscars commentary. This heightened focus underscores […]
Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of Apnimed’s lead […]
Sleep apnea and insomnia are two of the most prevalent sleep disorders, often coexisting and compounding the burden on patients’ quality of life. For sleep professionals, the challenge lies in unraveling the intertwined pathology of these conditions to provide effective treatment. Given this complex interplay, it is crucial to identify […]
Apnimed, Inc. announced the results of its Sleep Health Inquiries on Needs and Emotions (SHINE) survey of 1,500 people living with obstructive sleep apnea (OSA). The survey results revealed the significant and often devastating impact that people living with OSA experience daily. Many respondents reported feeling worn out or exhausted […]
